{"filing":{"accession_number":"0001193125-26-388621","cik":"0001503802","ticker":"KPTI","company_name":"Karyopharm Therapeutics Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-10","primary_document":"d94769d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526388621/d94769d8k.htm"},"events":[{"id":32811,"run_id":30165,"accession_number":"0001193125-26-388621","anchor_item_number":"2.04","event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Karyopharm failed to pay approximately $15.8 million in principal due September 10, 2026, under its Credit Agreement, constituting an Event of Default that triggers cross-default provisions, accelerates interest rates by 2.00% per annum, and exposes the company to potential acceleration of approximately $129.0 million in term loan obligations and $123.6 million in outstanding notes.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36076,"accession_number":"0001193125-26-388621","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple events of default under the Company's Credit Agreement and Indentures: non-payment of a ~$15.8 million principal installment due September 10, 2026; non-payment of cash interest due September 30, 2026; missed interest payments on convertible notes on June 30, 2026; and anticipated failure to satisfy a $25.0 million minimum liquidity covenant after October 10, 2026. These constitute \"Specified Defaults\" that triggered a forbearance agreement with lenders and noteholders. While the filing also involves a dilutive preferred stock issuance, the central disclosed event is the covenant breach and resulting financial distress requiring forbearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36077,"accession_number":"0001193125-26-388621","item_number":"2.04","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The company failed to pay approximately $15.8 million in principal due on September 10, 2026, under its Credit Agreement, which constitutes an \"Event of Default\" triggering cross-default provisions under related debt instruments. The default accelerates interest rates by 2.00% per annum and exposes the company to potential acceleration of approximately $129.0 million in term loan obligations and $123.6 million in outstanding notes, representing a material triggering event that increases direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32812,"run_id":30165,"accession_number":"0001193125-26-388621","anchor_item_number":"8.01","event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"The company disclosed substantial doubt about its ability to continue as a going concern, stating that absent additional funding or strategic transactions to extend cash runway beyond October 15, 2026, it will be unable to continue operations and may seek bankruptcy protection, liquidate assets, or cease operations.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36079,"accession_number":"0001193125-26-388621","item_number":"8.01","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The disclosure explicitly states that \"Absent additional funding or entry into one or more strategic transactions to extend the Company's cash runway beyond October 15, 2026, the Company will be unable to continue as a going concern and may have to consider seeking protection under the bankruptcy laws, liquidating assets or ceasing operations.\" This is an unmistakable going-concern disclosure indicating substantial doubt about the registrant's ability to continue operations, with a specific liquidity runway expiration date and explicit reference to bankruptcy as a potential outcome.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32813,"run_id":30165,"accession_number":"0001193125-26-388621","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Karyopharm issued unregistered Convertible Preferred Stock in a private placement to accredited investors in reliance on Section 4(a)(2) exemption, representing a material financing event affecting the company's capital structure and shareholder dilution.","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36078,"accession_number":"0001193125-26-388621","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of Convertible Preferred Stock by Karyopharm Therapeutics in reliance on Section 4(a)(2) exemption. The filing explicitly states the securities are being issued in a private placement to accredited investors without registration, which is a classic dilutive issuance. The reference to Item 1.01 (which typically covers material acquisitions or capital transactions) and the convertible nature of the preferred stock indicate this is a material financing event that would affect investor assessment of capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36076,"accession_number":"0001193125-26-388621","item_number":"1.01","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses multiple events of default under the Company's Credit Agreement and Indentures: non-payment of a ~$15.8 million principal installment due September 10, 2026; non-payment of cash interest due September 30, 2026; missed interest payments on convertible notes on June 30, 2026; and anticipated failure to satisfy a $25.0 million minimum liquidity covenant after October 10, 2026. These constitute \"Specified Defaults\" that triggered a forbearance agreement with lenders and noteholders. While the filing also involves a dilutive preferred stock issuance, the central disclosed event is the covenant breach and resulting financial distress requiring forbearance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11"},{"id":36077,"accession_number":"0001193125-26-388621","item_number":"2.04","item_title":null,"event_type":"covenant_breach","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The company failed to pay approximately $15.8 million in principal due on September 10, 2026, under its Credit Agreement, which constitutes an \"Event of Default\" triggering cross-default provisions under related debt instruments. The default accelerates interest rates by 2.00% per annum and exposes the company to potential acceleration of approximately $129.0 million in term loan obligations and $123.6 million in outstanding notes, representing a material triggering event that increases direct financial obligations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11"},{"id":36078,"accession_number":"0001193125-26-388621","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 3.02 discloses an unregistered private placement of Convertible Preferred Stock by Karyopharm Therapeutics in reliance on Section 4(a)(2) exemption. The filing explicitly states the securities are being issued in a private placement to accredited investors without registration, which is a classic dilutive issuance. The reference to Item 1.01 (which typically covers material acquisitions or capital transactions) and the convertible nature of the preferred stock indicate this is a material financing event that would affect investor assessment of capital structure and dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11"},{"id":36079,"accession_number":"0001193125-26-388621","item_number":"8.01","item_title":null,"event_type":"going_concern","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The disclosure explicitly states that \"Absent additional funding or entry into one or more strategic transactions to extend the Company's cash runway beyond October 15, 2026, the Company will be unable to continue as a going concern and may have to consider seeking protection under the bankruptcy laws, liquidating assets or ceasing operations.\" This is an unmistakable going-concern disclosure indicating substantial doubt about the registrant's ability to continue operations, with a specific liquidity runway expiration date and explicit reference to bankruptcy as a potential outcome.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T11:46:47.120032+00:00","company_name":"Karyopharm Therapeutics Inc.","ticker":"KPTI","filing_date":"2026-09-11"}]}